Skip to main content
. 2022 Jul;23(7):851–864. doi: 10.1016/S1470-2045(22)00284-4

Figure 4.

Figure 4

Progression-free survival and overall survival in the expanded PI3K/AKT/PTEN pathway-altered subgroup and pathway non-altered subgroup

Tick marks on plots show censoring events. (A) Genetic profile of tumours in each group as identified by expanded biomarker testing; two colours indicate that a tumour carried mutations in both genes. (B) Progression-free survival in the expanded pathway-altered subgroup. (C) Progression-free survival in the expanded pathway non-altered subgroup. (D) Overall survival in the expanded pathway-altered subgroup. (E) Overall survival in the expanded pathway non-altered subgroup. HR=hazard ratio.